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 {#epi412286-sec-0005}

Key PointsEpilepsy was reported in 1852 patients (83.6%) at baseline; of these, there were focal seizures in 67.5% and infantile spasms in 38.9% patientsEpilepsy was diagnosed before 2 years of age in approximately 79% of patientsThe rate of infantile spasms was higher in patients with *TSC2* mutation than in patients with *TSC1* mutation

2. INTRODUCTION {#epi412286-sec-0006}
===============

Epilepsy is one of the most common neurologic symptoms in patients with tuberous sclerosis complex (TSC), with reported prevalence from 62% to 93%.[1](#epi412286-bib-0001){ref-type="ref"}, [2](#epi412286-bib-0002){ref-type="ref"}, [3](#epi412286-bib-0003){ref-type="ref"} It is also a significant cause of morbidity and mortality in patients with TSC.[2](#epi412286-bib-0002){ref-type="ref"}, [4](#epi412286-bib-0004){ref-type="ref"} Epilepsy usually begins during the first months of life and in the majority before the first year.[5](#epi412286-bib-0005){ref-type="ref"} Early onset epilepsy often presents as focal seizures initially and can precede, coexist with, or evolve into infantile spasms.[5](#epi412286-bib-0005){ref-type="ref"}, [6](#epi412286-bib-0006){ref-type="ref"} However, patients with TSC can present with almost all seizure types such as tonic, atonic, or tonic‐clonic seizures.[6](#epi412286-bib-0006){ref-type="ref"} There are several therapeutic options available for the treatment of focal seizures and infantile spasms associated with TSC including antiepileptic drugs (AEDs), hormonal therapy, epilepsy surgery, ketogenic diet, and vagus nerve stimulation. However, about two‐thirds of patients develop treatment refractory epilepsies, associated with increased rates of intellectual disability and other TSC‐associated neuropsychiatric disorders (TAND).[6](#epi412286-bib-0006){ref-type="ref"}, [7](#epi412286-bib-0007){ref-type="ref"}

The natural history of epilepsy in TSC has been evaluated in only a handful of studies.[1](#epi412286-bib-0001){ref-type="ref"}, [2](#epi412286-bib-0002){ref-type="ref"}, [8](#epi412286-bib-0008){ref-type="ref"}, [9](#epi412286-bib-0009){ref-type="ref"} Most of these studies were retrospective in nature, reported a single‐center cohort, and had relatively small sample size. Only one large cohort was reported by Jeong et al, who evaluated the natural history of epilepsy in a cohort of patients with TSC enrolled from the United States and Belgium (n = 1816; 81.8% had history of focal seizures and 49.2% had infantile spasms).[2](#epi412286-bib-0002){ref-type="ref"} The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international study that enrolled patients from 170 centers across 31 countries worldwide. The baseline core data of TOSCA provided understanding of the overall TSC manifestations. The study showed epilepsy in 83.5% of patients, subependymal giant cell astrocytoma in 24.4%, and renal angiomyolipomas in 47.2%.[10](#epi412286-bib-0010){ref-type="ref"} Herein we report baseline data from TOSCA with the aim of describing the characteristics of epilepsy among this large cohort of patients with TSC.

3. METHODS {#epi412286-sec-0007}
==========

The methods of the TOSCA study have been described in detail previously.[11](#epi412286-bib-0011){ref-type="ref"} In short, TOSCA is a multicenter, international disease study designed to collect data, retrospectively and prospectively, on patients with TSC from several countries worldwide. Sites with specialists in managing one or more aspects of TSC (in children and adults) were included in the registry. Centers were dedicated mainly to epilepsy care but with almost 30% of patients (mainly adult) enrolled from other specialties as well.

The registry consists of a "core" section and 6 subsections ("petals"). In the "core" section, general information on patient background such as demographic data, family history, genotype, vital signs, prenatal history, clinical features of TSC across all organ systems, comorbidities, and rare manifestations were reported. Data were collected retrospectively and prospectively at baseline (first inclusion visit) and interim analysis was performed on this data collection. A prospective follow‐up observation period was up to 5 years, with regular visits scheduled at a minimum interval of 1 year to ensure an ongoing data stream. These follow‐up data were not included in this article. Subsections ("petals") represent specific research projects to record in‐depth data related to specific disease manifestations. Given that this is an international noninterventional study, evaluations included were those required for disease diagnosis and management according to the local best practice. The study protocol, therefore, did not specify any particular clinical instruments or laboratory investigations.

Patients of any age who fulfilled clinical criteria for TSC diagnosis were eligible if they had at least 1 documented visit for TSC within the previous 12 months or were newly diagnosed with TSC before participating in the registry. Variables were obtained on the basis of the most recent data collected during the last visit and included seizure type (focal seizures, infantile spasms, other seizures), age at onset of epilepsy, type of epilepsy treatment (grouped as γ‐aminobutyric acid (GABA)ergics, hormonal therapy, ketogenic diet, fructose derivatives, vagus nerve stimulator, mammalian target of rapamycin (mTOR) inhibitors, surgery, other modalities) and treatment outcome (eg, epilepsy resolved spontaneously, was controlled with treatment, or was not controlled with treatment). In addition, we compared the characteristics of epilepsy between the overall epilepsy cohort and those with epilepsy diagnosed before 2 years of age (early onset seizure group). The association between seizure type and genotype as well as between seizure control and intellectual ability was evaluated. Intellectual ability was evaluated by clinician or by formal neuropsychological test and categorized as normal (IQ \> 70), mild intellectual disability (ID) (IQ 51--70), moderate ID (IQ 36--50), severe ID (IQ 20‐35), and profound ID (IQ \< 20).

All eligible patients enrolled in the TOSCA study were considered in the analysis. Continuous variables were analyzed in terms of value (number of patients, mean, standard deviation, median, minimum and maximum), whereas categorical variables (eg, presence/absence of a condition or manifestation) were analyzed in terms of frequency distribution at baseline. Missing data were not imputed.

This study was designed, implemented, and reported in accordance with the Good Clinical Practice and the ethical principles specified in the Declaration of Helsinki.[12](#epi412286-bib-0012){ref-type="ref"} The protocol was approved by the local ethics committee at each center before patient enrollment.

4. RESULTS {#epi412286-sec-0008}
==========

4.1. Demographics and clinical characteristics {#epi412286-sec-0009}
----------------------------------------------

As of September 30, 2015 (data cutoff date for the third interim analysis), 2216 eligible patients from 170 sites across 31 countries worldwide were enrolled in the TOSCA study (Table [1](#epi412286-tbl-0001){ref-type="table"}). The third interim analysis included baseline data for all the patients enrolled in the study.

###### 

Patients enrolled from different countries in TOSCA (N = 2216)

  Countries          Number of patients, n (%)
  ------------------ ---------------------------
  Europe             
   France            228 (10.3)
   The Netherlands   224 (10.1)
   Germany           162 (7.3)
   Spain             119 (5.4)
   Belgium           110 (5.0)
   Italy             97 (4.4)
   Portugal          54 (2.4)
   Austria           52 (2.3)
   Poland            52 (2.3)
   United Kingdom    32 (1.4)
   Greece            30 (1.4)
   Slovakia          26 (1.2)
   Norway            24 (1.1)
   Sweden            23 (1.0)
   Romania           21 (0.9)
   Latvia            18 (0.8)
   Estonia           12 (0.5)
   Lithuania         11 (0.5)
   Slovenia          8 (0.4)
   Czech Republic    7 (0.3)
   Denmark           4 (0.2)
  Outside Europe     
   China             252 (11.4)
   Taiwan            140 (6.3)
   Australia         101 (4.6)
   Japan             98 (4.4)
   Turkey            91 (4.1)
   Russia            60 (2.7)
   Israel            59 (2.7)
   Thailand          50 (2.3)
   South Africa      31 (1.4)
   Korea             20 (0.9)

John Wiley & Sons, Ltd

Baseline patient demographics and clinical characteristics are summarized in Table [2](#epi412286-tbl-0002){ref-type="table"}. Baseline data were available for 1154 female (52.1%) and 1,062 male (47.9%) patients; 806 patients (36.4%) were adult (\>18 years) and 1410 (63.6%) were children or adolescents. The median age at consent was 13 years (range \< 1‐71). The mean age at TSC diagnosis was 7.0 years (median age 1 year; range \< 1‐69). Molecular testing for genetic mutations was performed for 1000 patients who met clinical criteria for TSC (45.1%). Of these, 638 patients (63.8%) had a *TSC2* mutation, 191 patients (19.1%) had a *TSC1* mutation, and 6 patients (0.6%) had both *TSC1* and *TSC2* mutations. No further molecular details were requested for this study. Of patients who had genetic molecular testing performed, no TSC mutation was identified in 144 patients (14.4%), whereas test results were not available for 9 patients (0.9%). Prenatal diagnosis of TSC was reported in 144 patients (6.5%) and 500 patients (22.6%) had relatives affected with TSC.

###### 

Baseline patient demographics and clinical characteristics (N = 2216)

  Characteristics                                                                          Baseline data
  ---------------------------------------------------------------------------------------- ---------------
  Age at diagnosis of TSC[a](#epi412286-note-0003){ref-type="fn"}, years, median (range)   1 (\<1‐69)
  Gender, n (%)                                                                            
   Male                                                                                    1062 (47.9)
   Female                                                                                  1154 (52.1)
  Patients with molecular testing, n (%)                                                   1000 (45.1%)
  Genetic testing, n (%)[b](#epi412286-note-0004){ref-type="fn"}                           
   No mutation identified                                                                  144 (14.4)
   *TSC1* mutation[c](#epi412286-note-0005){ref-type="fn"}                                 197 (19.7)
   *TSC2* mutation[c](#epi412286-note-0005){ref-type="fn"}                                 644 (64.4)
  Variation type, n (%)[d](#epi412286-note-0006){ref-type="fn"}                            
   Pathogenic mutation                                                                     678 (67.8)
   Variant of unknown significance                                                         66 (6.6)
  Time from first TSC clinical diagnosis to first molecular testing, months                
   Mean (SD)                                                                               80.8 (116.5)
   Median (range)                                                                          23 (\<1‐721)
  Patients with prenatal diagnosis, n (%)                                                  144 (6.5)
  Biologic mother/father evaluated for TSC, n                                              
   Mother                                                                                  936
   Father                                                                                  820
  TSC inherited from one parent, n                                                         
   Total                                                                                   51
   Mother                                                                                  30
   Father                                                                                  21
  Patients with affected relatives, n (%)[e](#epi412286-note-0007){ref-type="fn"}          
   Total                                                                                   500 (22.6)
   1                                                                                       275 (12.4)
   2                                                                                       138 (6.2)
   3                                                                                       50 (2.3)
   \>3                                                                                     54 (2.4)
  Patients with at least one blood relative participating in TOSCA, n (%)                  230 (10.4)

SD, standard deviation; TSC, tuberous sclerosis complex; TOSCA, TuberOus SClerosis registry to increase disease Awareness.

Data available for 2179 patients.

Information on the type of mutation was missing for 9 patients.

The count (n) includes 6 patients who had both *TSC1* and *TSC2* mutations.

The count (n) includes 23 patients who had both variation types.

Patients switching from one category to the other during the study visits were counted in each category.

John Wiley & Sons, Ltd

4.2. Characterization of epilepsy {#epi412286-sec-0010}
---------------------------------

Epilepsy was reported at the baseline visit in 1852 patients (83.6%) (overall epilepsy cohort). In this overall epilepsy cohort, a history of focal seizures was reported in 1250 patients (67.5%) and infantile spasms in 720 patients (38.9%). The co‐occurrence of focal seizures and epileptic spasms was reported in 380 patients (20.5%; Table [3](#epi412286-tbl-0003){ref-type="table"}). Of these, epileptic spasms occurred before focal seizures in 242 patients (13.1%) and focal seizures occurred first in 63 patients (3.4%). In 75 patients (4%), focal seizures and epileptic spasms were reported as starting concomitantly. The mean age at diagnosis of focal seizures was 2.7 years (median age 1 year; range \< 1‐66 years), whereas mean age at diagnosis of spasms was 0.4 years (median age \< 1 year; range \< 1‐30 years). In 691 patients (95.6%), infantile spasms were reported within the typical age range (before 2 years). In 22 patients (3%), it occurred between 2 and 5 years and in 10 patients (1.4%) at an older age. The differences in the occurrence rate and age at diagnosis of focal seizures and epileptic spasms (alone or in combination with other types) among patients with *TSC1* mutation and *TSC2* mutation are shown in Table [4](#epi412286-tbl-0004){ref-type="table"}. Infantile spasms were more frequent in patients with a *TSC2* mutation compared to those with a *TSC1* mutation (47.3% vs 23%).

###### 

Type of epilepsy and treatment outcomes in overall epilepsy cohort and in patients diagnosed at \<2 years at baseline

  Characteristics                                                         Overall epilepsy cohort (N = 1852), n (%)   Early onset seizure group, (N = 1461), n (%)
  ----------------------------------------------------------------------- ------------------------------------------- ----------------------------------------------
  Epilepsy type                                                                                                       
   Focal seizures[a](#epi412286-note-0009){ref-type="fn"}                 1250 (67.5)                                 984 (67.4)
   Infantile spasms[a](#epi412286-note-0009){ref-type="fn"}               720 (38.9)                                  684 (46.8)
   Focal seizures only                                                    765 (41.3)                                  530 (36.3)
   Infantile spasms only                                                  246 (13.3)                                  221 (15.1)
   Co‐occurrence of infantile spasms and focal seizures                   380 (20.5)                                  375 (25.7)
  Treatment[b](#epi412286-note-0010){ref-type="fn"} for infantile spasm                                               
  No. of patients who received treatment                                  696 (96.7)                                  663 (96.9)
  Type of treatment                                                                                                   
   GABAergics                                                             548 (78.7)                                  527 (79.5)
   ACTH                                                                   122 (17.5)                                  121 (18.3)
   mTOR inhibitors                                                        38 (5.5)                                    ‐
   Surgery                                                                29 (4.2)                                    ‐
   Ketogenic diet                                                         27 (3.9)                                    ‐
   Vagus nerve stimulator                                                 15 (2.2)                                    ‐
   Fructose derivatives                                                   9 (1.3)                                     ‐
  Treatment outcomes for infantile spasm                                                                              
   Resolved spontaneously                                                 23 (3.3)                                    34 (5.0)
   Controlled with treatment                                              530 (76.3)                                  506 (74.5)
   Not controlled with treatment                                          108 (15.5)                                  106 (15.6)
   Unknown                                                                34 (4 9)                                    33 (4.9)
  Treatment[b](#epi412286-note-0010){ref-type="fn"} for focal seizures                                                
  No. of patients who received treatment                                  1226 (98.1)                                 969 (98.5)
  Type of treatment                                                                                                   
   GABAergics                                                             803 (65.5)                                  683 (70.5)
   mTOR inhibitors                                                        95 (7.7)                                    ‐
   Surgery                                                                85 (6.9)                                    ‐
   Ketogenic diet                                                         58 (4.7)                                    ‐
   Vagus nerve stimulator                                                 47 (3.8)                                    ‐
   Fructose derivatives                                                   43 (3.5)                                    ‐
   ACTH                                                                   35 (2.9)                                    32 (3.3)
  Treatment outcomes for focal seizures                                                                               
   Resolved spontaneously                                                 9 (0.7)                                     10 (1.0)
   Controlled with treatment                                              713 (58.2)                                  552 (56.6)
   Not controlled with treatment                                          466 (38.0)                                  384 (39.3)
   Unknown                                                                38 (3.1)                                    30 (3.1)

ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin.

Alone or with other seizures.

As single therapy and in combination with other modalities.

John Wiley & Sons, Ltd

###### 

Characteristics of epilepsy according to mutation type

  Characteristics                                                         Overall epilepsy cohort with molecular testing   Early onset seizure group with molecular testing               
  ----------------------------------------------------------------------- ------------------------------------------------ -------------------------------------------------- ----------- ------------
  Epilepsy type                                                                                                                                                                           
   Focal seizures[a](#epi412286-note-0012){ref-type="fn"}                 113 (74.3)                                       409 (71.9)                                         75 (76.5)   350 (71.6)
   Infantile spasms[a](#epi412286-note-0012){ref-type="fn"}               35 (23)                                          269 (47.3)                                         34 (34.7)   260 (53.2)
   Infantile spasms only                                                  12 (7.9)                                         67 (11.8)                                          11 (11.2)   61 (12.5)
   Focal seizures only                                                    88 (57.9)                                        220 (38.7)                                         52 (53.1)   168 (34.4)
   Concomitant infantile spasms and focal seizures                        21 (13.8)                                        163 (28.6)                                         21 (21.4)   161 (32.9)
  Age at diagnosis, years                                                                                                                                                                 
   Focal seizures                                                                                                                                                                         
   Mean                                                                   3.7                                              2.2                                                1.1         0.9
   Median                                                                 2.0                                              \<1                                                1           \<1
   Range                                                                  \<1‐47                                           \<1‐59                                             \<1‐14      \<1‐16
   Infantile Spasms                                                                                                                                                                       
   Mean                                                                   0.3                                              0.3                                                0.3         0.2
   Median                                                                 \<1                                              \<1                                                \<1         \<1
   Range                                                                  \<1‐6                                            \<1‐5                                              \<1‐6       \<1‐4
  Treatment[b](#epi412286-note-0013){ref-type="fn"} for infantile spasm                                                                                                                   
  No. of patients who received treatment                                  33 (94.3)                                        264 (98.1)                                         32 (94.1)   256 (98.5)
  Type of treatment                                                                                                                                                                       
   GABAergics                                                             22 (66.7)                                        223 (84.5)                                         22 (68.8)   216 (84.4)
   ACTH                                                                   4 (12.1)                                         43 (16.3)                                          4 (12.5)    40 (15.6)
   Surgery                                                                2 (6.1)                                          15 (5.7)                                           ‐           ‐
   mTOR inhibitors                                                        2 (6.1)                                          16 (6.1)                                           ‐           ‐
   Vagus nerve stimulator                                                 1 (3)                                            9 (3.4)                                            ‐           ‐
   Fructose derivatives                                                   0                                                2 (0.8)                                            ‐           ‐
   Ketogenic diet                                                         0                                                14 (5.3)                                           ‐           ‐
  Treatment outcomes for infantile spasm                                                                                                                                                  
   Resolved spontaneously                                                 1 (3)                                            6 (2.3)                                            3 (8.8)     9 (3.5)
   Controlled with treatment                                              21 (63.6)                                        206 (78)                                           20 (58.8)   199 (76.8)
   Not controlled with treatment                                          10 (30.3)                                        40 (15.2)                                          10 (29.4)   40 (15.4)
   Unknown                                                                1 (3)                                            12 (4.5)                                           1 (2.9)     11 (4.2)
  Treatment[b](#epi412286-note-0013){ref-type="fn"} for focal seizures                                                                                                                    
  No. of patients who received treatment                                  113 (100)                                        402 (98.3)                                         75 (100)    348 (99.4)
  Type of treatment                                                                                                                                                                       
   GABAergics                                                             67 (59.3)                                        316 (78.6)                                         51(68)      280 (80.5)
   ACTH                                                                   2 (1.8)                                          7 (1.7)                                            2 (2.7)     7 (2.0)
   Surgery                                                                8 (7.1)                                          37 (9.2)                                           ‐           ‐
   mTOR inhibitors                                                        6 (5.3)                                          34 (8.5)                                           ‐           ‐
   Vagus nerve stimulator                                                 4 (3.5)                                          16 (4)                                             ‐           ‐
   Fructose derivatives                                                   6 (5.3)                                          14 (3.5)                                           ‐           ‐
   Ketogenic diet                                                         2 (1.8)                                          33 (8.2)                                           ‐           ‐
  Treatment outcomes for focal seizures                                                                                                                                                   
   Resolved spontaneously                                                 0                                                3 (0.7)                                            0           4 (1.1)
   Controlled with treatment                                              67(59.3)                                         229 (57.0)                                         44 (58.7)   195 (55.9)
   Not controlled with treatment                                          42 (37.2)                                        163 (40.5)                                         30 (40)     145 (41.5)
   Unknown                                                                4 (3.5)                                          7 (1.7)                                            1 (1.3)     5 (1.4)

ACTH, adrenocorticotropic hormone; mTOR, mammalian target of rapamycin.

Alone or with other seizures.

As single therapy and in combination.

John Wiley & Sons, Ltd

4.3. Treatment {#epi412286-sec-0011}
--------------

At baseline, a total of 1226 patients (98.1%) with focal seizures in the overall epilepsy cohort received treatment. The majority received GABAergics as a single agent or in combination with other treatment modalities (803, 65.5%). Additional treatment modalities included mTOR inhibitors (95, 7.7%), surgery (85, 6.9%), ketogenic diet (58, 4.7%), vagus nerve stimulation (47, 3.8%), fructose derivatives (43, 3.5%), and corticotropin (ACTH; 35, 2.9%). Focal seizures were controlled by treatment in 713 patients (58.2%), resolved spontaneously in 9 (0.7%), and were not controlled in 466 patients (38%). Outcome data were not available for 38 patients (3.1%).

A total of 696 patients (96.7%) in the overall epilepsy cohort received treatment for infantile spasms. The most frequent treatment modalities (as single agents or in combination with other treatment modalities) included GABAergics (548, 78.7%) and ACTH (122, 17.5%). Additional treatment modalities included mTOR inhibitors (38, 5.5%), surgery (29, 4.2%), ketogenic diet (27, 3.9%), vagus nerve stimulator (15, 2.2%), and fructose derivatives (9, 1.3%). Infantile spasms were controlled with treatment in 530 (76.3%), resolved spontaneously in 23 (3.3%), and were not controlled in 108 patients (15.5%). Outcome data were not available for 34 patients (4.9%). The type of treatment and overall outcome of focal seizures and infantile spasms in the patients diagnosed with epilepsy before the age of 2 years (early onset seizure group) were similar to those in the overall epilepsy cohort (Table [3](#epi412286-tbl-0003){ref-type="table"}). Type of treatment and overall outcome of focal seizures and infantile spasms in relation to mutation type are shown in Table [4](#epi412286-tbl-0004){ref-type="table"}.

4.4. Association between seizure control and intellectual ability {#epi412286-sec-0012}
-----------------------------------------------------------------

In the overall epilepsy cohort, a total of 563 of 1250 patients with focal seizures reported at baseline (45%) had received an evaluation of their intellectual abilities assessed by the clinician or by standardized tests depending on the local best practice. Of these, 229 patients (40.7%) had normal intellectual ability, whereas the degree of intellectual disability was recorded as mild in 178 (31.6%), moderate in 58 (10.3%), severe in 86 (15.3%), and profound in 12 patients (2.1%). Of 720 patients in the overall epilepsy cohort with a history of infantile spasms, 279 patients (38.8%) had been evaluated by formal tests for IQ. Of these, 61 patients (21.9%) had normal intellectual ability, whereas mild, moderate, severe, and profound degrees of intellectual disability were observed in 82 (29.4%), 73 (26.2%), 46 (16.5%) and 17 patients (6.1%), respectively. The proportion of patients with normal intellectual ability was higher in patients controlled with treatment than in those not controlled with treatment (23.5% vs 7.9%, patients with infantile spasms, and 47.5% vs 26.8%, patients with focal seizures; Figure [1](#epi412286-fig-0001){ref-type="fig"}).

![Effect of seizure control on intellectual ability. A, Patients with focal seizures. B, Patients with infantile spasms](EPI4-4-73-g001){#epi412286-fig-0001}

In the early onset seizure group, 459 of 984 patients (46.6%) diagnosed with focal seizures had been evaluated for IQ. Of these, 158 patients (34.4%) had normal intellectual ability, whereas mild, moderate, severe, and profound degrees of intellectual disability were observed in 151 (32.9%), 81 (17.6%), 57 (12.4%), and 12 (2.6%) patients, respectively. Among the 684 patients diagnosed with infantile spasms in the early onset seizure group, 273 (39.9%) were evaluated for IQ. A total of 59 patients (21.6%) had normal intellectual ability, whereas mild, moderate, severe, and profound degrees of intellectual disability was observed in 82 (30%), 71 (26%), 44 (16.1%), and 17 (6.2%) patients, respectively. Similar to the overall epilepsy cohort, the proportion of patients with normal intellectual ability was higher in the early onset seizure group that had been controlled than the group with uncontrolled focal seizure (41.2% vs 21.4%) and infantile spasms (23.3% vs 7.9%) after treatment.

5. DISCUSSION {#epi412286-sec-0013}
=============

The TOSCA study, which represents the largest cohort of patients with TSC described to date, enrolled patients from 31 countries and from various specialty clinics. The third interim analysis results showed an occurrence at baseline of epilepsy in about 83.6% of the of 2216 enrolled patients, which was in line with both the baseline "core" data of the TOSCA registry[10](#epi412286-bib-0010){ref-type="ref"} and other previous reports,[1](#epi412286-bib-0001){ref-type="ref"}, [8](#epi412286-bib-0008){ref-type="ref"}, [13](#epi412286-bib-0013){ref-type="ref"} confirming epilepsy to be the most common clinical presentation of TSC.

A database of 1816 individuals with TSC showed that focal seizures were present in 81.8% of the patients and infantile spasms in 49.2% of the patients included.[2](#epi412286-bib-0002){ref-type="ref"} In agreement with this report, focal seizures were also the most common seizure observed in our cohort, followed by infantile spasms. A history of infantile spasms was reported in about 38.9% patients with TSC in the TOSCA study, which was similar to that observed in a single center clinical case series of 291 patients by Chu‐Shore et al[1](#epi412286-bib-0001){ref-type="ref"}, which reported infantile spasms in approximately 37% of patients with TSC. However, Jeong et al.[2](#epi412286-bib-0002){ref-type="ref"} reported a slightly higher rate of infantile spasms (about 49.2%). This could be because patients with TSC in the series of Jeong et al were self‐enrolled by families that might have biased recruitment to more severe cases.

It has been reported that epilepsies associated with TSC most often have their onset during infancy or early childhood, although they may occur at any age, with focal seizures and infantile spasms being the most common seizure types.[5](#epi412286-bib-0005){ref-type="ref"}, [14](#epi412286-bib-0014){ref-type="ref"} In our study, epilepsy was diagnosed before 2 years of age in about 79% of patients, showing this early onset in the majority of patients. However, seizure onset occurred later in 27% of the cohort, and even in patients older than 40 years of age (about 7 patients \[0.6%\] diagnosed with focal seizures at age \>40 years). This emphasizes that patients with TSC remain at increased risk of epilepsy (mainly focal epilepsies) throughout their lifetime. The occurrence of infantile spasms was higher in the first 2 years (46.8% vs 38.9%), but the occurrence rate of focal seizures was similar (67.4% vs 67.5%) between the whole cohort and the early onset seizure group, respectively. Late‐onset epileptic spasms occurred in 2%‐6% of patients.[15](#epi412286-bib-0015){ref-type="ref"} This late occurrence of epileptic spasms was reported in structural epilepsies without specifying TSC.[15](#epi412286-bib-0015){ref-type="ref"}, [16](#epi412286-bib-0016){ref-type="ref"} Our data suggest that TSC can be considered as a cause of late‐onset epileptic spasms. These findings mainly highlight that infantile spasms and focal seizures occur at an early age in the majority of patients with TSC. Infantile spasms can precede, co‐occur, or follow focal seizures, with this co‐occurrence being a characteristic of TSC.[17](#epi412286-bib-0017){ref-type="ref"}

This emphasizes the importance of parental education and the potential role of serial electroencephalography (EEG) recordings to detect possible subclinical seizures. This has been suggested in patients with antenatal diagnosis of TSC or patients diagnosed with TSC before the onset of clinical seizures The question on the usefulness to initiate the treatment for subclinical seizures (seizures on EEG without clinical manifestations), or even paroxysmal EEG activity without subclinical seizures, is still under debate.[18](#epi412286-bib-0018){ref-type="ref"}, [19](#epi412286-bib-0019){ref-type="ref"} Two projects (EPISTOP[20](#epi412286-bib-0020){ref-type="ref"} and PREVENT[21](#epi412286-bib-0021){ref-type="ref"}) are ongoing with the aim of evaluating the impact of an early presymptomatic treatment to be administered at identification of EEG abnormalities without any clinical seizures reported or recorded in patients with TSC.

With respect to genotype, infantile spasms were more frequently seen in patients with a *TSC2* mutation compared to those with a *TSC1* mutation (47.3% vs 23%). Furthermore, patients with a *TSC2* mutation had an earlier onset of infantile spasms and focal seizures (Table [4](#epi412286-tbl-0004){ref-type="table"}). These findings reinforced the observations seen in previous studies evaluating the genotype‐phenotype relationships in patients with TSC,[1](#epi412286-bib-0001){ref-type="ref"}, [22](#epi412286-bib-0022){ref-type="ref"}and could suggest a better efficacy of earlier treatments.

GABAergic drugs were the most frequent therapy used in patients with focal seizures and patients with infantile spasms. The term GABAergic drugs was used for vigabatrin and did not include other GABAergic drugs. This finding is in line with the current recommendations that vigabatrin should be used as a first‐line AED treatment for infantile spasms with TSC and for focal seizures occurring before the age of 1 year.[5](#epi412286-bib-0005){ref-type="ref"}, [23](#epi412286-bib-0023){ref-type="ref"} A better outcome with vigabatrin initiation in association with hormonal therapy was reported in a cohort of patients with infantile spasms.[24](#epi412286-bib-0024){ref-type="ref"} However, patients with TSC were excluded from this study and the potential additional benefit from this inaugural bi‐therapy might need additional investigation. The number of patients resistant to treatment was higher for focal seizure (38%) than for infantile spasms (15.5%) and was independent of the mutation type. This emphasizes the better control of infantile spasms with a less efficacy on focal seizures control as they might persist or newly occur after the control of spasms. This finding is important for the development of new therapies for epilepsy in TSC, especially for focal seizures that were not controlled as well by available treatments. The recent EXIST 3 study showing higher efficacy of adjunctive everolimus therapy in patients with treatment‐refractory seizures associated with TSC compared to placebo, is promising in this regard.[25](#epi412286-bib-0025){ref-type="ref"}

The number of patients not controlled on treatment at baseline was much lower in our study (infantile spasms, 15.5%; focal seizures; 38%) than the 62.5% reported in a previous study by Chu‐Shore et al.[1](#epi412286-bib-0001){ref-type="ref"} This lower number of treatment‐resistant patients could be explained by the earlier diagnosis age shown by the high number of young patients enrolled in our study and by the fact that patients were diagnosed and managed in specialized reference centers that follow established recommended guidelines.[23](#epi412286-bib-0023){ref-type="ref"} There has been substantial progress in understanding of diagnosis and treatment of epilepsy in patients with TSC during the last decade. The recommendations of serial EEG studies before clinical seizures have allowed the detection of some patients with subtle or infraclinical seizures. In addition, current recommendation on the use of vigabatrin for both infantile spasms and focal seizures for infants might have contributed to this lower rate of pharmacoresistance.[5](#epi412286-bib-0005){ref-type="ref"}, [23](#epi412286-bib-0023){ref-type="ref"}

Studies exploring the efficacy of the ketogenic diet and vagus nerve stimulation in patients with TSC‐associated epilepsy showed that these nonpharmacologic therapies were effective in reducing seizure frequency.[26](#epi412286-bib-0026){ref-type="ref"}, [27](#epi412286-bib-0027){ref-type="ref"}, [28](#epi412286-bib-0028){ref-type="ref"}, [29](#epi412286-bib-0029){ref-type="ref"} Surprisingly, the ketogenic diet and vagus nerve stimulation were not commonly used in this cohort with a large proportion of patients with pharmacoresistant epilepsy. This cannot be totally due to lack of availability of such therapies, as many of the TOSCA sites were tertiary centers for TSC and epilepsy treatment. Some explanation can emerge explaining this lower use, as vagus nerve stimulation devices create difficulties for routine use of magnetic resonance imaging (MRI) of the brain or kidney, and the ketogenic diet is more difficult to achieve in patients with psychiatric and behavior disorders that are frequent in the patients with TSC presenting epilepsy. In addition, many of the severely delayed patients can be in specialized institutions where the ketogenic diet is not available. The number of patients that underwent epilepsy surgery was also relatively low in this cohort. Epilepsy surgery for patients with TSC needs specific expertise, as there is often more than a single tuber focus and surgery may need invasive monitoring of seizures to determine the resection area.[30](#epi412286-bib-0030){ref-type="ref"}, [31](#epi412286-bib-0031){ref-type="ref"} This might be the main limiting factor for epilepsy surgery but should be a reminder to refer patients with pharmacoresistant epilepsy early on to expert epilepsy surgery centers to define the possibility of such therapy that is showing fair results, even in patients with multiple foci.[32](#epi412286-bib-0032){ref-type="ref"}

The correlation between intellectual ability and seizure control in TSC has been reported.[33](#epi412286-bib-0033){ref-type="ref"}, [34](#epi412286-bib-0034){ref-type="ref"}, [35](#epi412286-bib-0035){ref-type="ref"}, [36](#epi412286-bib-0036){ref-type="ref"}, [37](#epi412286-bib-0037){ref-type="ref"} Patients with uncontrolled seizures had a higher rate of intellectual disability compared to those with controlled seizures. This association is known primarily for infantile spasms,[33](#epi412286-bib-0033){ref-type="ref"}, [34](#epi412286-bib-0034){ref-type="ref"}, [35](#epi412286-bib-0035){ref-type="ref"}, [36](#epi412286-bib-0036){ref-type="ref"}, [37](#epi412286-bib-0037){ref-type="ref"}but our cohort showed that pharmacoresistant focal seizures equally impact intellectual development in patients with TSC. Similar to these findings, the present study showed that a smaller proportion of patients who were controlled with treatment had intellectual disability compared to those uncontrolled in both groups of infantile spasms and focal seizures.

We acknowledge selection bias as one of the limitations of our study, given that recruitment was achieved through clinical centers with expertise in TSC. Milder cases, or those without seizure disorders in childhood, may not have been included. This study was recruited mainly from pediatric and adult centers for TSC dedicated to epilepsy care, but with almost 30% of patients (mainly adult) enrolled from other specialties as well. Despite the involvement of several specialty clinics, the rate of epilepsy observed in our study was very high (\>80%). Furthermore, due to the observational nature of the registry, only data collected from routine clinical practice were reported. This may in part explain the incomplete genetic and neuropsychological scores data, given the widespread differences in access to clinical evaluation of patients with TSC across the globe even in specialized centers, and the lack of access to neuropsychological evaluation. Nevertheless, participation of a large number of centers (170 sites in 31 countries) with complementary expertise has helped in the inclusion of a significant number of patients with TSC, which is likely to be representative of tertiary hospital clinical practice. The lower number of unknown data for epilepsy in this registry with a very large cohort reflects good quality data collection. Moreover, medical data reported in the registry were collected directly by the patients' physician and not provided by patients and families, ensuring a high level of medical accuracy. Finally, therapies were recorded in groups of AEDs, as the purpose of this registry was to increase disease awareness and to report epilepsy characteristics, and not to evaluate the efficacy of specific therapies.

In conclusion, TOSCA provides valuable insights into the characteristics of epilepsy in patients with TSC. Our aim was to increase awareness on the disease and to present a picture of patients' characteristics and interventions in a very large number of centers dedicated for TSC care around the world. The findings in this study support previous studies highlighting the higher prevalence of epilepsy in patients with TSC with onset during infancy or early childhood, the correlation between seizure control and intellectual outcome, and the ongoing need for therapies for both infantile spasms and focal seizures as well as for even closer developmental observations correlated with these. The findings also emphasize the better seizure control compared to previous studies that might be multifactorial encompassing earlier diagnosis and a widespread use of the international guidelines for therapies. However, standardized neuropsychological and psychiatric assessment is still lacking in many countries, even in reference centers, and this should be better addressed and implemented.[10](#epi412286-bib-0010){ref-type="ref"}, [38](#epi412286-bib-0038){ref-type="ref"} Finally, the surgery as a rare recourse in the therapy arsenal should be further investigated and a closer interaction with expert centers for epilepsy surgery should be encouraged.

Further analysis of collected data of the TOSCA study will provide more details in understanding the treatment interventions and outcomes and might inform on the development of our knowledge on a rare disease exploring time‐related changes through these data regarding different aspects as age of diagnosis, therapies, and therapy responses.
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